Drug Profile
Research programme: targeted anti-inflammatory therapeutics - Chroma Therapeutics
Alternative Names: CHR-3242; CHR-3620; CHR-4432Latest Information Update: 26 May 2010
Price :
$50
*
At a glance
- Originator Chroma Therapeutics
- Class
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Histone deacetylase inhibitors; P38 mitogen-activated protein kinase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Rheumatoid arthritis
Most Recent Events
- 26 May 2010 No development reported - Preclinical for Autoimmune disorders in United Kingdom (unspecified route)
- 26 May 2010 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
- 26 May 2010 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)